

B3

(23) (TWICE AMENDED) A method of treating [a] an intraocular structural disorder of an eye comprising introducing [intraocularly] into the intraocular structure under treatment a substantially transparent liquid perfluorocarbon or substituted derivative thereof in an amount effective to treat said intraocular structural disorder.

B4

(26) (AMENDED) A method of treating [a] an intraocular structural disorder [in a structure] of an eye comprising introducing a liquid comprising a liquid perfluorocarbon or substituted derivative thereof into [said] a structure of [said] an eye under treatment selected from the group consisting of anterior chamber, posterior chamber, cornea, lens and vitreous body in an amount effective to treat said disorder.

Remarks

The undersigned applicant's attorney gratefully acknowledges the telephone interview with Examiner Waddell on April 12, 1984, in which it was agreed that the outstanding §112 rejection to remaining Claims 1-16 and 20-26 was overcome by the amendment of existing claims to recite the fact that the method is directed in a more generic aspect to the treatment of intraocular structural disorders of the eye. Previously the Examiner had objected to "a disorder". It was urged by applicant's attorney during the course of the telephone interview that the specification supported a number of disorders which were all intraocular structural disorders which may be treated with the method of this invention by introducing the perfluorocarbon liquid into the intraocular structure under treatment

including (a) defective vitreous or aqueous (specification page 8, lines 1 et sequel); (b) transparentization of the cornea or lens to restore vision (specification page 8, lines 2 et sequel); (c) treatment of retinal tears or detachments (specification page 8, lines 6 et sequel); (d) radiopaque agents to x-ray intraocular structures as a diagnostic technique (specification page 10, lines 4 et sequel); (e) removal of foreign agents or blood which penetrate the vitreous (specification page 3, lines 6 et sequel); and (f) the alleviation of glaucoma by replacement of aqueous humor (specification pages 6 and 7, lines 29 et sequel). Each of such techniques are directed to the treatment of intraocular structural disorders by the intraocular introduction of the liquid. Accordingly, applicant submits that the specification does indeed support the broader method claims directed to the treatment of intraocular structural disorders as represented by the specification. It would indeed be too limiting in such a basic invention as that herein claimed to restrict applicant's rights to the specific structural disorders disclosed which are exemplary of the broader method wherein such disorders fall into a class. Wherefore, as agreed, claims as now amended overcome the §112 rejection. Accordingly, Claims 1-16 and 20-26 are now in condition for allowance along with previously allowed Claims 17-19 and 27-30.


It is to be noted that Claims 20-22 were previously rejected under §103 as being unpatentable over Wada. Claims 20-22 are now dependent from Claim 1 and specifically recite, as supported by the specification at page 10, lines 4 et sequel, that a radiopaque liquid perfluorocarbon can be introduced into the eye to X-ray the intraocular structural disorder. For the reasons advanced in connection with the

allowability of the broader Claim 1 and for the further reason that there is no prior art disclosure of a perfluorocarbon liquid as a contrast agent in the eye, reconsideration and allowance of Claims 20-22 is respectfully requested. Wada does not even teach perfluorocarbons as contrast agents. While certain perfluorocarbons are known contrast agents, applicant's claims 20-22 are directed to the X-raying of an intraocular structural disorder by the employment of a radiopaque perfluorocarbon. This is wholly absent from the patent disclosure of Wada and applicant knows of no prior art which suggests such a method. Wada has no recognition or teaching of a perfluorocarbon as a contrasting agent let alone employing it in the eye of an animal to detect a structural disorder as required by Claims 20-22. Therefore, reconsideration of Claims 20-22 is respectfully requested, especially now since such claims are dependent from Claim 1.

In view of the above amendments, this application is considered to be in condition for allowance and early allowance is respectfully solicited.

Respectfully submitted,

WOOD, HERRON & EVANS


David J. Josephic
Reg. No. 22,849

2700 Carew Tower
Cincinnati, Ohio 45202
(513) 241-2324